- BetterLife Pharma (CSE:BETR) has applied for patent protection of new compositions of 2-bromo-LSD to treat cluster headaches, PTSD and other related disorders
- TD-0148A is a second-generation lysergic acid diethylamide derivative molecule that does not cause hallucinations and is not subject to controlled substance regulations
- BetterLife is already in the advanced stages of GMP manufacturing TD-0148A
- BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products
- BetterLife Pharma Inc. (BETR) opened trading at C$0.28 per share
BetterLife Pharma (BETR) has applied for patent protection of new compositions of 2-bromo-LSD.
These compositions are used in the treatment of cluster headaches, PTSD and other related disorders.
BetterLife is developing one of the new compositions of 2-bromo-LSD covered by its newly filed provisional patent application.
TD-0148A is a second-generation lysergic acid diethylamide derivative molecule that does not cause hallucinations and is therefore not subject to controlled substance regulations. In addition, the synthesis of TD-1048A is via non-controlled substance synthetic routes and therefore not subject to controlled substance regulatory restrictions.
BetterLife is already in the advanced stages of GMP manufacturing TD-0148A and initiated the necessary preclinical IND-enabling studies for TD-0148A. TD-0148A is currently in preclinical pharmacology and other IND-enabling studies and in 2022, BetterLife will file its IND and start Phases 1 and 2 in healthy subjects for major depressive disorder.
Ahmad Doroudian, CEO of BetterLife commented,
“The inventions covered by this provisional patent filing hold great promise, and helps us advance on our path to becoming a leader in the psychedelic drug space which is estimated to become a US$6.85-billion industry by 2027. We are excited to be developing and bringing to market treatments addressing cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.”
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing two compounds, TD-0148A and TD-010, to treat neurological disorders such as depression, cluster headaches and anxiety.
BetterLife Pharma Inc. (BETR) opened trading at C$0.28 per share.
